FibroGen's pamrevlumab Fast Track'd for IPF

|About: FibroGen (FGEN)|By:, SA News Editor

The FDA designates FibroGen's (FGEN) anti-CTGF antibody pamrevlumab for Fast Track review for the treatment of ideopathic pulmonary fibrosis (IPF).

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

Subscribe for full text news in your inbox